Rebecca W. Silbermann

Hematology

3181 SW Sam Jackson Park Rd
Portland, OR 97239

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

The Case | When the diagnosis is more than skin deep.

The Case | When the diagnosis is more than skin deep.

Journal: Kidney international

Published: April 28, 2026

Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome.

Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome.

Journal: Blood advances

Published: February 18, 2026

Successful Tarlatamab Rechallenge After Recurrent High-Grade Cytokine Release Syndrome in Chromothripsis-Mediated SCLC: A Case Report.

Successful Tarlatamab Rechallenge After Recurrent High-Grade Cytokine Release Syndrome in Chromothripsis-Mediated SCLC: A Case Report.

Journal: JTO clinical and research reports

Published: December 29, 2025

Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation.

Redefining functional high-risk multiple myeloma in the context of upfront quadruplet therapy and autologous stem cell transplantation.

Journal: Cancer

Published: November 22, 2025

Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant.

Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant.

Journal: British journal of haematology

Published: November 14, 2025

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.

Journal: Blood

Published: October 07, 2025

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.

Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy.

Journal: Blood

Published: October 07, 2025

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses.

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses.

Journal: Clinical lymphoma, myeloma & leukemia

Published: September 23, 2025

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses.

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses.

Journal: Blood cancer journal

Published: June 06, 2025

Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS.

Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUS.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 23, 2025

Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma.

Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma.

Journal: Blood

Published: November 13, 2024

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy.

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy.

Journal: Blood cancer journal

Published: November 05, 2024

Showing 1-12 of 54

Last Updated: 09/26/2026